The Case For and Against Using Cannabinoids to Treat Glaucoma
Cannabinoids can lower eye pressure and may protect retinal nerve cells, but delivery challenges, short duration of action, and side effects have limited their clinical use for glaucoma.
Quick Facts
What This Study Found
The review examined evidence on cannabinoids for glaucoma from multiple angles. Exogenous cannabinoids do lower intraocular pressure (IOP), the main modifiable risk factor for glaucoma. Research has also identified a complete endocannabinoid system within the eye, including CB1 and CB2 receptors, that naturally helps regulate IOP.
Beyond pressure reduction, cannabinoids showed neuroprotective properties that could help preserve retinal ganglion cells, the neurons that die in glaucoma. This dual mechanism (pressure lowering plus neuroprotection) makes cannabinoids theoretically attractive.
However, the IOP-lowering effect of smoked or oral cannabis lasts only 3 to 4 hours, requiring frequent dosing. Systemic side effects including psychoactivity, cardiovascular changes, and reduced blood pressure (which may actually worsen glaucoma by reducing blood flow to the optic nerve) remain significant barriers. Topical eye drop formulations have been difficult to develop due to cannabinoids' poor water solubility.
Key Numbers
IOP-lowering effect lasts approximately 3-4 hours with systemic cannabinoid administration. Glaucoma affects the retinal ganglion cells. Both CB1 and CB2 receptors are present in ocular tissues.
How They Did This
This was a narrative review of published literature covering the ocular endocannabinoid system, mechanisms of cannabinoid-induced IOP reduction, neuroprotective properties of cannabinoids, clinical survey data, bioavailability challenges, and adverse effects.
Why This Research Matters
Glaucoma is a leading cause of irreversible blindness worldwide. While cannabinoids can lower eye pressure, this review clarifies why they have not replaced conventional glaucoma treatments. The short duration of effect, delivery challenges, and the paradox that lowering blood pressure might harm the optic nerve all complicate the picture.
The Bigger Picture
Despite decades of interest, cannabinoids have not become standard glaucoma treatment. The gap between the theoretical promise (pressure reduction plus neuroprotection) and practical limitations (short duration, side effects, delivery problems) illustrates a broader pattern in cannabinoid medicine where mechanism-based promise does not always translate into clinical utility.
What This Study Doesn't Tell Us
This is a narrative review, not a systematic review or meta-analysis. The authors selected studies without a formal search protocol. Much of the evidence for neuroprotection comes from animal models. Clinical trial data on cannabinoids for glaucoma remains limited.
Questions This Raises
- ?Could new drug delivery systems (nanoparticles, sustained-release formulations) overcome the bioavailability challenges?
- ?Would a cannabinoid that provides neuroprotection without psychoactivity be viable for glaucoma?
- ?Are there specific patient populations for whom cannabinoid-based glaucoma treatment might be more appropriate?
Trust & Context
- Key Stat:
- Cannabis lowers eye pressure for only 3-4 hours, requiring dosing 6-8 times daily
- Evidence Grade:
- Moderate evidence from a narrative review synthesizing decades of research, though limited by lack of systematic methodology.
- Study Age:
- Published in 2017. Comprehensive overview of the cannabinoid-glaucoma literature.
- Original Title:
- The arguments for and against cannabinoids application in glaucomatous retinopathy.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 86, 620-627 (2017)
- Authors:
- Panahi, Yunes, Manayi, Azadeh, Nikan, Marjan, Vazirian, Mahdi
- Database ID:
- RTHC-01477
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat glaucoma?
Cannabis can temporarily lower eye pressure, but the effect lasts only 3-4 hours, making it impractical as a standalone treatment. Conventional eye drops and surgeries remain far more effective for sustained pressure control.
Could CBD eye drops work for glaucoma?
Developing effective cannabinoid eye drops has been challenging due to poor water solubility. Some research has explored various formulation strategies, but no commercially available cannabinoid eye drop has proven clinically effective for glaucoma.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01477APA
Panahi, Yunes; Manayi, Azadeh; Nikan, Marjan; Vazirian, Mahdi. (2017). The arguments for and against cannabinoids application in glaucomatous retinopathy.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 86, 620-627. https://doi.org/10.1016/j.biopha.2016.11.106
MLA
Panahi, Yunes, et al. "The arguments for and against cannabinoids application in glaucomatous retinopathy.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017. https://doi.org/10.1016/j.biopha.2016.11.106
RethinkTHC
RethinkTHC Research Database. "The arguments for and against cannabinoids application in gl..." RTHC-01477. Retrieved from https://rethinkthc.com/research/panahi-2017-the-arguments-for-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.